{"meshTags":["Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antibodies, Neoplasm","Antineoplastic Agents","Disease-Free Survival","Humans","Leukemia, Lymphocytic, Chronic, B-Cell","Remission Induction","Treatment Outcome"],"meshMinor":["Antibodies, Monoclonal","Antibodies, Monoclonal, Humanized","Antibodies, Neoplasm","Antineoplastic Agents","Disease-Free Survival","Humans","Leukemia, Lymphocytic, Chronic, B-Cell","Remission Induction","Treatment Outcome"],"publicationTypes":["Comment","Letter"],"title":"Is alemtuzumab really the single active agent for treatment of chronic lymphocytic leukemia?","pubmedId":"19001335"}